Percentage of expenses for co-promotion of sales and medical affairs.

No definition available.

Name:	mdvn_CoPromotionOfSalesAndMedicalAffairsPercentage
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Maximum dollar amount of milestone payments eligible to be received under a collaboration arrangement.

+ References

No definition available.

+ Details

Name:	mdvn_MaximumEligibleMilestonePaymentsUnderCollaborationArrangement
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Dollar amount of milestone payments earned to date pursuant to collaboration agreement.

+ References

No definition available.

+ Details

Name:	mdvn_MilestonePaymentsEarnedToDateUnderCollaborationAgreement
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Remaining milestone payments that are eligible to be received in the future under collaboration arrangements.

+ References

No definition available.

+ Details

Name:	mdvn_RemainingFutureMilestonePaymentsEligibleToReceiveUnderCollaborationArrangements
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Royalties received at percentage rate ranging.

+ References

No definition available.

+ Details

Name:	mdvn_RoyaltiesReceivedAtPercentageRateRanging
Namespace Prefix:	mdvn_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Share Percentage Of Development And Commercialization Cost Under Former Collaboration

+ References

No definition available.

+ Details

Name:	mdvn_SharePercentageOfDevelopmentAndCommercializationCostUnderFormerCollaboration
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	dei_LegalEntityAxis=mdvn_AstellasPharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mdvn_CommercialCostSharingPaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mdvn_DevelopmentCostSharingPaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mdvn_DevelopmentMilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mdvn_SalesMilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreements - Collaboration Agreements with Astellas and Pfizer- Additional Information (Detail) (USD $)	12 Months Ended	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2008	Dec. 31, 2009
Collaborative agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Co-promotion of sales and medical affairs percentage	50.00%
Astellas Pharma Inc. [Member] \| Collaborative agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty received on ex-U.S. sales per collaboration arrangement	Low teens to the low twenties
Up-front cash payment arrangement [Member] \| Pfizer [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-refundable, upfront cash payment		$ 225,000,000
Up-front cash payment arrangement [Member] \| Astellas Pharma Inc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-refundable, upfront cash payment			110,000,000
Development cost-sharing payments [Member] \| Pfizer [Member] \| Collaborative agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Share percentage of developing and commercializing dimebon		60.00%
Commercial cost sharing-payments [Member] \| Medivation [Member] \| Collaborative agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Share percentage of developing and commercializing dimebon		40.00%
Development milestone payments [Member] \| Astellas Pharma Inc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Eligible to receive milestone payments	335,000,000
Milestone payments earned	335.0
Sales milestone payments [Member] \| Astellas Pharma Inc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Eligible to receive milestone payments	320,000,000
Milestone payments earned	75.0
Remaining future milestone payments eligible to receive	245,000,000